Answers are grounded in this paper and cite their sources.
Uterine fibroids are benign monoclonal tumors that occur in approximately 70% of women of reproductive age. Despite many studies, the causes of leiomyomas are still not fully understood. To date, a huge amount of data has been accumulated all over the world on the use of metagenomic, metatranscriptome, and metamethylome methods for the analysis of complete genomes of tumors, including leiomyomas. More than 100 genetic polymorphisms associated with a hereditary predisposition to the occurrence of leiomyomas have been identified. However, despite numerous publications on meta-transcriptomics, meta-methylomics, and GWAS studies in uterine leiomyoma, the results of these studies have hardly been used to develop new therapeutic agents. Further research should be aimed at developing new effective drugs for the prevention, treatment and prevention of recurrence of uterine fibroids. Aim. To improve the efficiency of diagnosis, treatment and identification of risk factors for recurrence by analyzing modern ideas about genetic changes that cause the development of genetically different variants of uterine fibroids, as well as generalizing all approaches to non-surgical methods of treating the disease based on the latest data from metagenomic, metatranscriptome and metamethylome methods for analyzing whole genomes.
No takes yet. Share an insight, caveat, or question.
Adamyan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: